Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus - Yamasaki, Makoto; Miyata, Hiroshi; Tanaka, Koji; Shiraishi, Osamu; Motoori, Masaaki; Peng, Y.F.; Yasuda, Takushi; Yano, Masahiko; Shiozaki, Hitoshi; Mori, Masaki; Doki, Yuichiro (Oncology, 2011)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Cancer; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - secondary; Chemotherapy; Cisplatin - administration & dosage; Clinical Study; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Esophagus; Female; Fluorouracil - administration & dosage; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Lymphatic Metastasis; Male; Medical sciences; Middle Aged; Recurrence; Side effects; Taxoids - administration & dosage; Treatment Outcome; Tumors; Chemotherapy; Squamous cell carcinoma of esophagus; Cisplatin; Docetaxel; Fluorouracil; Antineoplastic agent; Relapse; Multicenter study; Esophageal disease; Esophagus squamous cell carcinoma; Cancerology; Taxane derivatives; Phase II trial; Advanced stage; Antimitotic; Platinum II Complexes; Human; Drug combination; Enzyme; Fluoropyrimidine derivatives; Transferases; Enzyme inhibitor; Malignant tumor; Thymidylate synthase; Alkylating agent; Treatment; Antimetabolic; Methyltransferases; Phase I trial; Pyrimidine derivatives; Digestive diseases; Combined treatment; Cancer